While fiber can trigger IBS symptoms in some patients, dehydration amplifies both medication side effects and IBS-related constipation
Mounjaro (Tirzepatide) Dual action: targets both GLP-1 and GIP receptors Strong appetite suppression & improved blood sugar control Clinical trials show average body weight loss up to 22.5% over 72 weeks Wegovy (Semaglutide) Targets GLP-1 receptors only Licensed in the UK for obesity and cardiovascular protection STEP trials show 1521% body weight loss A new 7.2mg dose is expected in late 2025, with results potentially matching Mounjaro Both treatments are once-weekly injections, prescribed alongside healthy diet and lifestyle changes
These peptides have their ends joined by chemical bridges , making them less flexible and harder for enzymes to break down
The Japan semaglutide market was valued at USD 242.7 million as of 2025, which is further projected to be worth USD 299.2 million by the end of 2026 and also increase to USD 1,955.5 million, along with a 23.2% growth rate by the end of 2035
Appearance: White powder
The connection between GLP-1 activity and sleep likely stems from how these medications affect neurotransmitters like serotonin and dopamine, which regulate both appetite and circadian rhythm
